What Can Move Roche’s Stock By 40% Next Year?
‘+40% To Roche’s Stock In 2016 If EBITDA Grows 5% & EV/EBITDA Multiple Expands 30%
+30% To EV/EBITDA Multiple If:
- Drugs With Peak Sales ~ 20% Of Roche’s Sales ($10 Bil) Launched/Near Launch In 2016 (Historical Benchmark -> Table 1 At Bottom)
Have more questions about Roche? See the links below.
- What Drove 15% Growth in Roche’s Earnings Between 2011-2014 Even Though Other Big Pharma Companies Suffered A Decline?
- Why Is Market Assigning Low Earnings Multiple To Roche Despite Its Biotech Focus?
- Can Roche Grow Its Earnings By 15% In The Next 3 Years?
- With Biosimilars Getting Approval In Europe, Does Roche’s 2016 EPS Face A Meaningful Risk?
- How Can Roche Get 25% Boost In Revenues In 5 Years?
- Can Emerging Biosimilar Competition Cause > 10% Downside To Roche’s Valuation?
- Here Is Why We Are Bullish On Roche
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)